| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
867 Stock Overview
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.
Rewards
Risk Analysis
No risks detected for 867 from our risk checks.
China Medical System Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$12.24 |
| 52 Week High | HK$20.80 |
| 52 Week Low | HK$10.02 |
| Beta | 0.60 |
| 1 Month Change | 14.61% |
| 3 Month Change | -0.65% |
| 1 Year Change | -38.74% |
| 3 Year Change | 62.98% |
| 5 Year Change | -3.01% |
| Change since IPO | 0.16% |
Recent News & Updates
Shareholder Returns
| 867 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -1.9% | 1.5% | 0.5% |
| 1Y | -38.7% | -40.9% | -20.3% |
Return vs Industry: 867 exceeded the Hong Kong Pharmaceuticals industry which returned -40.9% over the past year.
Return vs Market: 867 underperformed the Hong Kong Market which returned -20.3% over the past year.
Price Volatility
| 867 volatility | |
|---|---|
| 867 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in HK Market | 13.7% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 867 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 867's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 5,292 | Kong Lam | https://www.cms.net.cn |
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company’s products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications.
China Medical System Holdings Fundamentals Summary
| 867 fundamental statistics | |
|---|---|
| Market Cap | CN¥25.64b |
| Earnings (TTM) | CN¥3.02b |
| Revenue (TTM) | CN¥8.34b |
8.5x
P/E Ratio3.1x
P/S RatioIs 867 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 867 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.34b |
| Cost of Revenue | CN¥2.09b |
| Gross Profit | CN¥6.25b |
| Other Expenses | CN¥3.23b |
| Earnings | CN¥3.02b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.23 |
| Gross Margin | 74.93% |
| Net Profit Margin | 36.19% |
| Debt/Equity Ratio | 13.1% |
How did 867 perform over the long term?
See historical performance and comparisonDividends
4.7%
Current Dividend Yield40%
Payout RatioValuation
Is 867 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 867?
Other financial metrics that can be useful for relative valuation.
| What is 867's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | CN¥25.64b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.8x |
| Enterprise Value/EBITDA | 6.8x |
| PEG Ratio | 1.1x |
Price to Earnings Ratio vs Peers
How does 867's PE Ratio compare to its peers?
| 867 PE Ratio vs Peers |
|---|
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.8x | ||
570 China Traditional Chinese Medicine Holdings | 10.8x | 13.6% | HK$24.4b |
3320 China Resources Pharmaceutical Group | 8.9x | 1.9% | HK$33.5b |
2096 Simcere Pharmaceutical Group | 12.9x | 1.1% | HK$22.8b |
512 Grand Pharmaceutical Group | 6.7x | n/a | HK$16.0b |
867 China Medical System Holdings | 8.5x | 8.0% | HK$30.0b |
Price-To-Earnings vs Peers: 867 is good value based on its Price-To-Earnings Ratio (8.5x) compared to the peer average (9.8x).
Price to Earnings Ratio vs Industry
How does 867's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 867 is good value based on its Price-To-Earnings Ratio (8.5x) compared to the Hong Kong Pharmaceuticals industry average (9.5x)
Price to Earnings Ratio vs Fair Ratio
What is 867's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 8.5x |
| Fair PE Ratio | 13.9x |
Price-To-Earnings vs Fair Ratio: 867 is good value based on its Price-To-Earnings Ratio (8.5x) compared to the estimated Fair Price-To-Earnings Ratio (13.9x).
Share Price vs Fair Value
What is the Fair Price of 867 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 867 (HK$12.24) is trading below our estimate of fair value (HK$37.85)
Significantly Below Fair Value: 867 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: 867 is poor value based on its PEG Ratio (1.1x)
Discover undervalued companies
Future Growth
How is China Medical System Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score
3/6Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
8.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 867's forecast earnings growth (8% per year) is above the savings rate (1.6%).
Earnings vs Market: 867's earnings (8% per year) are forecast to grow slower than the Hong Kong market (16.6% per year).
High Growth Earnings: 867's earnings are forecast to grow, but not significantly.
Revenue vs Market: 867's revenue (11.1% per year) is forecast to grow faster than the Hong Kong market (10.1% per year).
High Growth Revenue: 867's revenue (11.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 867's Return on Equity is forecast to be high in 3 years time (22.2%)
Discover growth companies
Past Performance
How has China Medical System Holdings performed over the past 5 years?
Past Performance Score
5/6Past Performance Score 5/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
14.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 867 has high quality earnings.
Growing Profit Margin: 867's current net profit margins (36.2%) are lower than last year (36.4%).
Past Earnings Growth Analysis
Earnings Trend: 867's earnings have grown by 14.6% per year over the past 5 years.
Accelerating Growth: 867's earnings growth over the past year (19.2%) exceeds its 5-year average (14.6% per year).
Earnings vs Industry: 867 earnings growth over the past year (19.2%) exceeded the Pharmaceuticals industry 16.1%.
Return on Equity
High ROE: 867's Return on Equity (23.5%) is considered high.
Discover strong past performing companies
Financial Health
How is China Medical System Holdings's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 867's short term assets (CN¥7.4B) exceed its short term liabilities (CN¥2.1B).
Long Term Liabilities: 867's short term assets (CN¥7.4B) exceed its long term liabilities (CN¥879.6M).
Debt to Equity History and Analysis
Debt Level: 867 has more cash than its total debt.
Reducing Debt: 867's debt to equity ratio has reduced from 26% to 13.1% over the past 5 years.
Debt Coverage: 867's debt is well covered by operating cash flow (148.5%).
Interest Coverage: 867 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Dividend
What is China Medical System Holdings's current dividend yield, its reliability and sustainability?
Dividend Score
5/6Dividend Score 5/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
4.70%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 867's dividend (4.7%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.71%).
High Dividend: 867's dividend (4.7%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.81%).
Stability and Growth of Payments
Stable Dividend: 867's dividends per share have been stable in the past 10 years.
Growing Dividend: 867's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (40.2%), 867's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (52.2%), 867's dividend payments are covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
10.1yrs
Average board tenure
CEO
Kong Lam (57 yo)
no data
Tenure
CN¥4,540,000
Compensation
Dr. Lam Kong founded and serves as the Chairman and Chief Executive Officer of China Medical System Holdings Limited and has been its Executive Director since December 18, 2006. Mr. Lam serves as President...
CEO Compensation Analysis
Compensation vs Market: Kong's total compensation ($USD677.51K) is above average for companies of similar size in the Hong Kong market ($USD360.49K).
Compensation vs Earnings: Kong's compensation has been consistent with company performance over the past year.
Board Members
Experienced Board: 867's board of directors are seasoned and experienced ( 10.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
China Medical System Holdings Limited's employee growth, exchange listings and data sources
Key Information
- Name: China Medical System Holdings Limited
- Ticker: 867
- Exchange: SZSC
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$30.021b
- Shares outstanding: 2.45b
- Website: https://www.cms.net.cn
Number of Employees
Location
- China Medical System Holdings Limited
- Island Place Tower
- Unit 2106
- North Point
- Hong Kong
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/02 00:00 |
| End of Day Share Price | 2022/06/30 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.